A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

  • White, Michelle (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 69161
NMA SSA Reference Number: SSA/69161/MonH-2021-247469(v1)
Monash Health Reference: RES-20-0000-794A
StatusNot started


  • phase 3 study
  • breast cancer
  • treatment safety
  • treatment efficacy